Behandlingsophør skal overvejes i følgende situationer: • Hos HBeAg- positive patienter uden cirrose skal behandlingen mindst gives i 6- 12 måneder efter HBe- serokonvertering (clearing af HBeAg og HBV- DNA med påvisning af anti- HBe) er bekræftet eller indtil HBs- serokonvertering eller der er bevis for ophør af effekt.
Treatment discontinuation should be considered as follows: • In HBeAg-positive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection) is confirmed or until HBs seroconversion or there is evidence of loss of efficacy.